Cycle on Sep 21, 2026

I'll start by reviewing the topic's open threads, prior notes, and pulling market data for the core GLP-1 companies.

I have the thread list and prior notes. Now let me pull market views for the remaining core companies (Amgen, Viking, Structure Therapeutics).

All five core companies pulled. Notable signals: GPCR down 30.7% in a month (RSI 17), VKTX has an imminent binary readout, NVO took a Morgan Stanley Sell downgrade. Now let me search for the latest GLP-1 news to explain these moves and check on open watch threads.

The Viking maintenance readout appears imminent but may not have dropped yet. GPCR's 30% drop came despite positive data — worth digging into. Let me check the latest news on the Viking readout, the Novo v. Lilly injunction, and broader GLP-1 market news.

Excellent material. Key developments: the Fierce Pharma oral GLP-1 tracker (Sept 18 update), Lilly's ">30% of new oral patients" claim (Reuters Sept 14), and — critically — Novo Nordisk is hosting a capital markets day in London **today** (Sept 21). Let me check for the CMD outcome, whether Viking's maintenance readout has landed, and MariTide Phase 3 progress.

The Novo capital markets day is happening today in London — Reuters confirms investors are demanding medium-term targets and a roadmap beyond semaglutide. Viking's maintenance readout is still pending (guidance maintained for Q3). Now let me check MariTide's Phase 3 progress and why Structure Therapeutics fell 30% despite good data.

Now I understand GPCR's drop — a "sell-the-news" valuation reset after Sept 8 data despite strong results. MariTide's MARITIME-SWITCH Phase 3 is initiated; T2D Phase 3s still pending. Let me check adjacent-sector impacts (food/beverage, medtech) and the pricing/reimbursement front (Novo's $675 cut, TrumpRx).

I have a good picture forming. Let me fetch the key primary sources I'll cite: the Reuters article on Lilly's >30% oral claim, today's Reuters piece on the Novo CMD, and Structure's Sept 8 press release.

I'm writing up this cycle's findings now — seven evidence-backed notes, then a watch registration, then I'll close the cycle. First batch of four notes:

First note saved. The second call was malformed — let me write the remaining six notes properly, starting with the Novo ziltivekimab and Structure Therapeutics updates.

Two more saved. Now the Viking and Amgen updates:

Four saved. Now the final two notes — the ad-lawsuit update and the new pricing-reset note:

All seven notes are saved. I spotted a typo'd wikilink in the pricing note — let me fix that, and register a watch for today's Novo capital markets day outcomes (the event is in progress in London right now):

All findings are persisted and the new watch is registered. Closing the cycle now.

Cycle complete. Here's what this research cycle surfaced and persisted: ## Seven findings written (6 updates + 1 new) 1. **Oral GLP-1 battle narrows** (`eli-lilly-foundayo-orforglipron-fda-approval`) — Foundayo crossed 47K weekly scripts and claims >30% of new U.S. oral obesity patients (Reuters, Sept 14), though Novo's Wegovy pill still leads 3.4x at ~161K weekly scripts. Tirzepatide now holds ~57% of the total GLP-1 market (vs 49.5% a year ago). 2. **Novo's IL-6 program collapses** (`novo-nordisk-cardiovascular-pipeline-ziltivekimab`) — Ziltivekimab's HERMES and ATHENA Phase 3 trials terminated Sept 8 after ZEUS failed, killing Novo's cardiovascular "third leg" right before today's capital markets day. Morgan Stanley downgraded to Sell Sept 12. 3. **Structure Therapeutics sell-the-news** (`structure-therapeutics-aleniglipron-access-ii-results`) — 16.2% weight loss at 72 weeks with no plateau, plus first-ever oral small-molecule amylin data, yet the stock fell 14.7% on the day and is down ~31% in a month (RSI 17). Q4 Body Composition/T2DM/SWITCH readouts are the next catalysts. 4. **Viking's live binary** (`viking-therapeutics-oral-vk2735-phase-2-venture`) — CEO reaffirmed the VK2735 maintenance readout for Q3 (by Sept 30); options are pricing it as a binary event. Success bar: retain ≥75% of week-21 weight loss on less-frequent dosing. 5. **Amgen's MARITIME-SWITCH Phase 3 initiated** (`amgen-maritide-phase-2-results-maritime-phase-3`) — directly targets patients switching from weekly tirzepatide/semaglutide to monthly/quarterly MariTide. AMGN's 10% monthly drawdown is Lp(a) spillover, not obesity news. 6. **Novo v. Lilly ad lawsuit** (`novo-nordisk-eli-lilly-advertising-lawsuit`) — preliminary injunction motion filed; no ruling yet, watch stays open. 7. **NEW: GLP-1 pricing reset** (`glp1-pricing-trumprx-list-price-cuts`) — TrumpRx is live at $149–$299/month vs $1,028–$1,349 list; Novo's $675 list cut lands Jan 1, 2027; Medicare at $245; self-pay floor now ~$150. ## Watch registered - **Novo CMD outcomes** — the London capital markets day is happening *today*; next cycle should capture new medium-term targets, zenagamtide-vs-CagriSema prioritization, and M&A signals. ## Watches checked, none fired Viking maintenance data (pending, due by Sept 30), MariTide T2D Phase 3 initiations, the injunction ruling, and Structure's Q4 readouts all remain open.